Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension
May 06, 2021 08:00 ET | Sumitovant Biopharma
Cary, N.C. and Basel, Switzerland, May 06, 2021 (GLOBE NEWSWIRE) -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...
Cary, N.C. and Basel, Switzerland s Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS
April 26, 2021 11:34 ET | Sumitovant Biopharma
Cary, N.C. and Basel, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...
Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting
April 21, 2021 08:00 ET | Sumitovant Biopharma
Cary, N.C. and Basel, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...
Sumitovant Biopharma Completes Acquisition of Urovant Sciences
March 29, 2021 08:00 ET | Sumitovant Biopharma
NEW YORK, LONDON, IRVINE, CA & BASEL, SWITZERLAND, March 29, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma and Urovant Sciences (formerly Nasdaq: UROV) jointly announced today the completion of...
Sumitovant Biopharma’s Portfolio of Innovative Companies Achieve Significant Clinical and Corporate Milestones in its Third Quarter of Operation
March 02, 2021 07:00 ET | Sumitovant Biopharma
LONDON and NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- — Sumitovant Biopharma. today announced that its five subsidiary healthcare companies (Myovant, Urovant, Enzyvant, Altavant and Spirovant )...
Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID
February 18, 2021 07:00 ET | Sumitovant Biopharma
Cary, N.C. and Basel, Switzerland, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...
Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
February 17, 2021 20:02 ET | Sumitovant Biopharma
New York, London, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of Medicine...
UPDATE: Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
January 26, 2021 17:27 ET | Sumitovant Biopharma
NEW YORK, LONDON,, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences’ Phase 3 SPIRIT...
Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
January 26, 2021 14:28 ET | Sumitovant Biopharma
NEW YORK, LONDON,, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences’ Phase 3 SPIRIT...
Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership
January 26, 2021 07:00 ET | Sumitovant Biopharma
PHILADELPHIA, PA, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Spirovant Sciences, a gene therapy company developing treatments and cures for respiratory diseases including cystic fibrosis, today announced the...